“In an era of molecular medicine, genetic evaluation and new therapy modalities pathology is a central discipline in all these things. Because we assist both the surgeon and the oncologist and their decision is based on the pathologic workup of the tissue”, says Prof. Tibor Tot (Sweden). In the symposium he chaired at the joint IAP/ESP 2016 Congress speakers from Australia, USA and Europe made their contributions to the update of pathologic knowledge and practise that helps clinicians and their breast cancer patients.